Skip to main content

ESC 2016: beneficial effects of allogeneic mesenchymal stem cells in HF patients

By 30 Agosto 2016Settembre 15th, 2021No Comments
Dai congressiNews

Javed Butler describes the main findings from the Phase IIa CardioCell’s Heart Failure study on the safety and efficacy of intravenous infusion of ischemia-tolerant allogeneic mesenchymal stem cells in patients with non-ischemic cardiomyopathy. He also outlines the main challenges of cardiovascular therapies in cancer patients.